<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Salvage therapies for &lt;EM&gt;H. pylori&lt;/EM&gt; infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Salvage therapies for <em>H. pylori</em> infection</h1>
<div class="graphic"><div class="figure"><div class="ttl">Salvage therapies for <em>H. pylori</em> infection</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Regimen</td> <td class="subtitle1">Drugs (doses)*</td> <td class="subtitle1">Dosing frequency</td> <td class="subtitle1">Duration (days)</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Bismuth quadruple</td> <td>PPI (standard <span style="white-space: nowrap;">dose<sup>¶</sup>)</span></td> <td>Twice daily</td> <td class="divider_bottom centered" rowspan="4">14</td> </tr> <tr> <td> <p>Bismuth subcitrate (120 to 300 mg [not available in US] or 420 mg [available in North America and elsewhere as part of Pylera combination <span style="white-space: nowrap;">pill])<sup>[1]</sup></span></p> <p><strong>or</strong></p> Bismuth subsalicylate (300 or <span style="white-space: nowrap;">524 mg)<sup>[1]</sup></span></td> <td>Four times daily</td> </tr> <tr> <td>Tetracycline (500 mg)</td> <td>Four times daily</td> </tr> <tr class="divider_bottom"> <td>Metronidazole (500 mg)</td> <td>Three to four times daily</td> </tr> <tr> <td class="divider_bottom" rowspan="3">Levofloxacin triple</td> <td>PPI (high <span style="white-space: nowrap;">dose or high potency<sup>¶</sup>)</span></td> <td>Twice daily</td> <td class="divider_bottom centered" rowspan="3">14</td> </tr> <tr> <td>Levofloxacin (500 mg)</td> <td>Once daily</td> </tr> <tr class="divider_bottom"> <td>Amoxicillin (750 mg)</td> <td>Three times daily</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Clarithromycin quadruple<sup>[2]</sup></td> <td>PPI (standard <span style="white-space: nowrap;">dose<sup>¶</sup>)</span></td> <td>Twice daily</td> <td class="divider_bottom centered" rowspan="4">14</td> </tr> <tr> <td>Clarithromycin (500 mg)</td> <td>Twice daily</td> </tr> <tr> <td>Bismuth subsalicylate (300 or 524 mg)<sup>[1]</sup></td> <td>Four times daily</td> </tr> <tr class="divider_bottom"> <td>Tetracycline (500 mg)</td> <td>Four times daily</td> </tr> <tr> <td class="divider_bottom" rowspan="3">Rifabutin <span style="white-space: nowrap;">triple<sup>◊</sup></span></td> <td>PPI (high dose or high potency<span style="white-space: nowrap;"><sup>¶</sup>)</span></td> <td>Twice daily</td> <td class="divider_bottom centered" rowspan="3">14</td> </tr> <tr> <td>Rifabutin (300 mg)</td> <td>Once daily</td> </tr> <tr class="divider_bottom"> <td>Amoxicillin (750 mg)</td> <td>Three times daily</td> </tr> <tr class="divider_bottom"> <td>Rifabutin <span style="white-space: nowrap;">triple<sup>◊</sup></span><br/> (commercially available combination capsules)</td> <td>Four (4) omeprazole-amoxicillin-rifabutin combination capsules (each capsule contains 10/250/12.5 mg)</td> <td>Three times daily</td> <td class="centered">14</td> </tr> <tr> <td rowspan="2">High-dose dual</td> <td>PPI (high <span style="white-space: nowrap;">dose<sup>¶</sup>)</span></td> <td>Twice daily</td> <td class="centered" rowspan="2">14</td> </tr> <tr> <td>Amoxicillin (1 gram three times daily or 750 mg four times daily)</td> <td>Three to four times daily</td> </tr> </tbody></table></div><div class="graphic_footnotes">FDA: United States Food and Drug Administration; PPI: proton pump inhibitor.<br/>* Doses are for adults with normal kidney function. Dose adjustment is warranted in patients with kidney function impairment for certain antibiotics (eg, levofloxacin, rifabutin, clarithromycin if end-stage disease).<br/>¶ Standard dose of orally administered proton pump inhibitors include: Lansoprazole 30 mg daily, omeprazole 20 mg daily, pantoprazole 40 mg daily, rabeprazole 20 mg daily, esomeprazole 20 mg daily, or dexlansoprazole 30 mg daily.<br/>High-dose proton pump inhibitors are double the standard dose. High-potency proton pump inhibitors include esomeprazole or rabeprazole.<br/>◊ Rifabutin-containing regimens should be reserved for patients with ≥3 previous eradication failures. Rifabutin is an inducer of cytochrome P450 drug metabolism (ie, accelerates drug metabolism); assess potential drug interactions before use.</div><div class="graphic_reference">Reference: 

<ol>
<li>Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastro 2016; 151:51.</li>
<li>Shah SC, Iyer PG, Moss, SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology 2021; 160:1831.</li></ol>Adapted by permission from Macmillan Publishers Ltd: American Journal of Gastroenterology. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017; 112:212. Copyright © 2017. <a href="http://www.nature.com/ajg" target="_blank">www.nature.com/ajg</a>.</div><div id="graphicVersion">Graphic 112172 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
